Northern Trust’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-42,193
| Closed | -$29.5K | – | 4629 |
|
|
2023
Q1 | $29.5K | Sell |
42,193
-39
| -0.1% | -$36 | ﹤0.01% | 4376 |
|
|
2022
Q4 | $38K | Sell |
42,232
-37
| -0.1% | -$107 | ﹤0.01% | 4349 |
|
|
2022
Q3 | $254K | Buy |
42,269
+4,334
| +11% | +$24.6K | ﹤0.01% | 3756 |
|
|
2022
Q2 | $157K | Sell |
37,935
-823
| -2% | -$2.9K | ﹤0.01% | 4011 |
|
|
2022
Q1 | $148K | Sell |
38,758
-528
| -1% | -$2.38K | ﹤0.01% | 4231 |
|
|
2021
Q4 | $177K | Buy |
39,286
+7,088
| +22% | +$36K | ﹤0.01% | 4240 |
|
|
2021
Q3 | $150K | Buy |
32,198
+7,898
| +33% | +$41.8K | ﹤0.01% | 4280 |
|
|
2021
Q2 | $171K | Sell |
24,300
-84,436
| -78% | -$455K | ﹤0.01% | 4212 |
|
|
2021
Q1 | $642K | Sell |
108,736
-14,004
| -11% | -$84.8K | ﹤0.01% | 3742 |
|
|
2020
Q4 | $566K | Sell |
122,740
-834
| -0.7% | -$3.6K | ﹤0.01% | 3692 |
|
|
2020
Q3 | $481K | Sell |
123,574
-3,432
| -3% | -$69K | ﹤0.01% | 3619 |
|
|
2020
Q2 | $3.65M | Buy |
127,006
+67,852
| +115% | +$1.57M | ﹤0.01% | 2708 |
|
|
2020
Q1 | $1.27M | Buy |
59,154
+6,008
| +11% | +$136K | ﹤0.01% | 3097 |
|
|
2019
Q4 | $1.05M | Buy |
53,146
+46,185
| +663% | +$656K | ﹤0.01% | 3379 |
|
|
2019
Q3 | $104K | Buy |
+6,961
| New | +$108K | ﹤0.01% | 3918 |
|
Northern Trust's STSA Position: Q2 2023 in Review
Northern Trust sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 42,193 shares — an estimated $29.5K sold.
Northern Trust first reported a position in STSA in Q3 2019 and held it in 15 quarters. The position peaked at $3.65M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Northern Trust reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 42,193 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $29.5K.
- Northern Trust first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Northern Trust's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $3.65M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.